

ADVANCES IN PHARMACEUTICAL PRODUCT
DEVELOPMENT AND RESEARCH SERIES

BASIC FUNDAMENTALS OF DRUG DELIVERY

Edited by

RAKESH K. TEKADE

*National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, Gandhinagar,
Gujarat, India; Formerly with the Department of Pharmaceutical Technology, School of Pharmacy,
International Medical University, Kuala Lumpur, Malaysia*

Contents

List of Contributors xiii

About the Editor xvii

1. Scientific Rationale for Designing Controlled Drug Delivery Systems

ANU HARDENIA, NEHA MAHESHWARI,
SHIV SHANKAR HARDENIA, SUNIL KUMAR DWIVEDI,
RAHUL MAHESHWARI AND RAKESH K. TEKADE

- 1.1 Conventional Drug Delivery Systems and Limitations 2
- 1.2 Controlled Release Drug Delivery System 4
- 1.3 Design of CRDDS: Understanding of Factors 7
- 1.4 Approaches for the Design of CRDDS 15
- 1.5 Medical Rationale of CRDDS 17
- 1.6 The Biological Rationale for CRDDS 21
- 1.7 Conclusion 24
- Acknowledgment 24
- Abbreviations 24
- References 25

2. Current Developments in Excipient Science: Implication of Quantitative Selection of Each Excipient in Product Development

MOUSUMI KAR, YASHU CHOURASIYA,
RAHUL MAHESHWARI AND RAKESH K. TEKADE

- 2.1 An Introduction to Excipient Science 30
- 2.2 Excipients Used in Different Dosage Formulations: Role in Product Development 44
- 2.3 Redefining Excipients for Advanced Product Development: Effect on Product Quality 73
- 2.4 Multifunctional Mineral Excipients 73
- 2.5 A Note on Excipient Incompatibilities: Ways to Counter the Issue 74
- 2.6 Quality by Design Approach in Excipient Selection 75

2.7 Safety Assessment of Excipients: US FDA Perspective 75

2.8 Excipients in the Label and Package Leaflet of Medicinal Products for Human Use 76

2.9 Conclusion 77

Acknowledgments 77

Abbreviations 77

References 78

3. Fundamentals of Polymers Science Applied in Pharmaceutical Product Development

VINOD KUMAR DHOTE, KANIKA DHOTE,
SHARAD PRAKASH PANDEY, TRIPTI SHUKLA,
RAHUL MAHESHWARI, DINESH K. MISHRA
AND RAKESH K. TEKADE

- 3.1 Understanding Polymer and Polymer Science 86
- 3.2 Chemistry and Synthesis Protocols 89
- 3.3 Classification of Polymers 92
- 3.4 Analytical Techniques for the Characterization of Polymers 95
- 3.5 Application of Polymers in Medicine: Recent Case Studies 97
- 3.6 Development of Tailored Polymers for Drug Delivery and Therapy 102
- 3.7 Conclusion 107
- Acknowledgment 107
- Abbreviations 107
- References 108

4. Use of Polymers in Controlled Release of Active Agents

SHARAD PRAKASH PANDEY, TRIPTI SHUKLA, VINOD
KUMAR DHOTE, DINESH K. MISHRA,
RAHUL MAHESHWARI AND RAKESH K. TEKADE

- 4.1 Introduction to Controlled Release System 114
- 4.2 Introduction to Polymer Science 116

- 4.3 Polymers Used in the Controlled Release System 123
- 4.4 Factors Affecting Biodegradation of Polymers 149
- 4.5 Polymers for Response-Based Release 154
- 4.6 Polymer Conjugate Systems for Controlled Release of Various Bioactive 156
- 4.7 Modern Polymers for Modified Release: Polymers for the 21st Century 160
- 4.8 Conclusion 162
- Acknowledgment 162
- Abbreviations 163
- References 164
- 5. Copolymers and Block Copolymers in Drug Delivery and Therapy**
NIDHI RAVAL, DNYANESHWAR KALYANE,
RAHUL MAHESHWARI AND RAKESH K. TEKADE
- 5.1 Introduction to Polymers, Copolymers, and Block Copolymers in Drug Delivery 174
- 5.2 Importance of Copolymers and Block Copolymers in Drug Delivery Science 178
- 5.3 Types of Copolymers 178
- 5.4 Biodegradable Copolymers and Block Copolymers 187
- 5.5 The Functionality of Copolymers and Block Copolymers in Drug Delivery 188
- 5.6 Patented Polymer Therapeutics 194
- 5.7 Future Developments and Conclusion 194
- Acknowledgment 196
- Abbreviations 196
- References 197
- Further Reading 201
- 6. Pharmaceutical and Biomedical Applications of Polymers**
PRAN KISHORE DEB, SARAH FALAH KOKAZ,
SARA NIDAL ABED, ANANT PARADKAR
AND RAKESH K. TEKADE
- 6.1 Introduction 204
- 6.2 Classification and Characteristics of Polymers 209
- 6.3 Synthesis of Polymers 219
- 6.4 Mechanisms of Drug Release From Polymers 220
- 6.5 Characterization of Polymers 223
- 6.6 Factors Influencing Degradation of Polymers 225
- 6.7 The Applications of Polymers in Different Pharmaceutical Systems 225
- 6.8 Conclusion 253
- Abbreviations 254
- References 255
- 7. Levels of Drug Targeting**
KHUSHWANT S. YADAV, DINESH K. MISHRA, ASHWINI
DESHPANDE AND ANIL M. PETHE
- 7.1 Targeted Drug Delivery Systems: Advantages and Requirements 270
- 7.2 Scheme and Rationale for Drug Targeting 271
- 7.3 Vital Properties Influencing Drug Targeting 273
- 7.4 Approaches and Levels of Drug Targeting 282
- 7.5 Application to Therapeutic Areas 296
- 7.6 Targeted Medical Products: A Market Review 298
- 7.7 Future Aspects and Conclusion 300
- Acknowledgment 300
- Abbreviations 300
- References 301
- Further Reading 305
- 8. Ligands for Targeted Drug Delivery and Applications**
DEVESH KAPOOR, SHAILENDRA BHATT,
MANISH KUMAR, RAHUL MAHESHWARI
AND RAKESH K. TEKADE
- 8.1 Introduction 308
- 8.2 Approaches for Targeting 309
- 8.3 Basics of the Fabrication of a Most Favorable Ligand-Targeted Drug 309
- 8.4 Targeting Ligands 312
- 8.5 Ligand-Targeted Products in the Market 336
- 8.6 Conclusion 337
- Acknowledgments 337
- Abbreviation 337
- References 338
- Further Reading 342

9. Transportation and Biointeraction Properties in Nanomaterials Across Biological Systems

DNYANESHWAR KALYANE, RAHUL MAHESHWARI, NIDHI RAVAL, ABHAY S. CHAUHAN AND RAKESH K. TEKADE

- 9.1 Nanomaterials: An Overview 344
- 9.2 Nanoparticle—Membrane Interactions: Elastic Theory 345
- 9.3 Cell: Important Components in Biointeraction With Nanomaterials 345
- 9.4 Important Properties of Nanomaterials Involved in Biointeraction 346
- 9.5 Transportation of Biomaterials Inside the Cell: Mechanisms Involved 348
- 9.6 Interaction of Nanomaterials With Blood and Blood Components 351
- 9.7 Interaction of Nanomaterials With BBB 353
- 9.8 Interaction of Nanomaterials With Macrophages 354
- 9.9 Interaction of Nanomaterials With Protein Corona 356
- 9.10 Interaction of Nanomaterials With DNA and Other Nuclear Materials 356
- 9.11 Interaction of Nanomaterials With Cellular Organelles 358
- 9.12 What Level of Understanding Has Been Reached With Regard to Nanoparticle Interactions? 361
- 9.13 Policy Dilemma: Small Particles, Unknown Risks—Do We Need More Law? 362
- 9.14 Conclusion 362
- Acknowledgment 363
- Abbreviations 363
- References 363

10. Importance of Physicochemical Characterization of Nanoparticles in Pharmaceutical Product Development

NIDHI RAVAL, RAHUL MAHESHWARI, DNYANESHWAR KALYANE, SUSANNE R. YOUNGREN-ORTIZ, MAHAVIR B. CHOUGULE AND RAKESH K. TEKADE

- 10.1 Nanoparticles in Pharmaceuticals 370
- 10.2 Importance of Nanoparticles Characterization 371
- 10.3 Various Techniques to Characterize Nanoparticles Used for Pharmaceutical Applications 372

- 10.4 Conclusion 392
- Acknowledgment 395
- Abbreviations 395
- References 396
- Further Reading 400

11. Biodegradable Block Copolymers and Their Applications for Drug Delivery

VANDANA SONI, VIKAS PANDEY, SAKET ASATI, VISHAL GOUR AND RAKESH K. TEKADE

- 11.1 Introduction 402
- 11.2 Classification of Block Copolymers 405
- 11.3 Synthetic Methods of Block Copolymer 407
- 11.4 Types of Biodegradable Copolymer 408
- 11.5 Some Biodegradable Block Copolymers 414
- 11.6 Biodegradable Block Copolymers as Drug Delivery System 423
- 11.7 Applications of Biodegradable Block Copolymer 428
- 11.8 Packaging and Sterilization 437
- 11.9 Conclusion 438
- Abbreviations 438
- References 440
- Further Reading 447

12. Bionanotechnology in Pharmaceutical Research

RAHUL MAHESHWARI, GARIMA JOSHI, DINESH K. MISHRA AND RAKESH K. TEKADE

- 12.1 Nanotechnology and Bionanotechnology: At a Glance 450
- 12.2 Advantages of Bionanotechnology Research 452
- 12.3 Role of Bionanotechnology in Pharmaceutical Research 454
- 12.4 Challenges in the Development of Bionanotechnology-Based Products 462
- 12.5 Hazards of Bionanotechnology: Toxicity Consideration 464
- 12.6 Nanobiotechnology Based Marketed Formulations: An Updated Summary 466
- 12.7 Future Prospects and Conclusion 466
- Acknowledgments 467
- Abbreviations 467
- References 468

13. Design and Evaluation of Ophthalmic Delivery Formulations

VANDANA SONI, VIKAS PANDEY, RAHUL TIWARI,
SAKET ASATI AND RAKESH K. TEKADE

- 13.1 Introduction 475
- 13.2 Structure of Eye 475
- 13.3 Lead From Anatomy and Physiology of Eye Towards Ocular Product Development 478
- 13.4 Considerations of Tear Film and Lachrymal Drainage for the Design of Ocular Drug Delivery System 479
- 13.5 Various Ocular Disorders 481
- 13.6 Types of Formulation for Ocular Delivery 484
- 13.7 A Note on Bioadhesive Approaches for Enhanced Ocular Delivery of Drug 503
- 13.8 Barriers to Transscleral Drug Delivery to the Retina 510
- 13.9 Factors Affecting Designing of the Formulations 514
- 13.10 Factors Influencing Drug Retention 516
- 13.11 In Vitro Techniques for Evaluation of Ocular Drug Delivery System 520
- 13.12 Ex Vivo Models to Evaluate Ocular Drug Delivery Systems 523
- 13.13 Animal Models to Evaluate Ocular Drug Delivery Systems 525
- 13.14 Recent Patents and Regulatory Status on Ophthalmic Delivery Formulations 526
- 13.15 Conclusion 528
- Abbreviations 528
- References 529
- Further Reading 538

14. Design and Fabrication of Brain-Targeted Drug Delivery

VANDANA SONI, VIKAS PANDEY, SAKET ASATI,
PRIYANKA JAIN AND RAKESH K. TEKADE

- 14.1 Introduction 540
- 14.2 Diseases Related to BBB 542
- 14.3 Anatomy and Physiology of Blood-Brain Barrier: Vital Concepts of BBB Drug Delivery 544
- 14.4 Efflux Mechanisms in Drug Transport to the Brain 554
- 14.5 Physiological Factors Affecting Brain Uptake 555

- 14.6 Strategies for Drug Delivery to Brain 557
- 14.7 In Vitro and In Vivo Methods for Brain Drug Delivery 578
- 14.8 Marketed Formulations Available as the Brain-Targeted Drug Delivery System 581
- 14.9 Conclusion 581
- Acknowledgments 581
- Abbreviations 582
- References 582
- Further Reading 593

15. Cutaneous and Transdermal Drug Delivery: Techniques and Delivery Systems

DINESH K. MISHRA, VIKAS PANDEY,
RAHUL MAHESHWARI, PIYUSH GHODE
AND RAKESH K. TEKADE

- 15.1 Introduction to Transdermal Drug Delivery 596
- 15.2 Skin as an Obstacle: Things to Know for Transdermal Research 598
- 15.3 Factors Affecting the Design of Transdermal Drug Delivery 601
- 15.4 Strategies for Transdermal Drug Delivery 605
- 15.5 Traditional Approaches for Transdermal Drug Delivery: Room for Formulation Advancements 608
- 15.6 Advanced Techniques for Transdermal Drug Delivery 608
- 15.7 Conclusion 643
- Acknowledgment 644
- Abbreviations 644
- References 644

16. Protein/Peptide Drug Delivery Systems: Practical Considerations in Pharmaceutical Product Development

PRAN KISHORE DEB, OMAR AL-ATTRAQCHI,
BALAKUMAR CHANDRASEKARAN,
ANANT PARADKAR AND RAKESH K. TEKADE

- 16.1 Introduction 652
- 16.2 Structural Characteristics and Properties of Proteins and Peptides 653
- 16.3 Overview of Pharmacokinetics of Therapeutic Proteins and Peptides 654
- 16.4 Formulation Stability of Therapeutic Proteins and Peptides Products 657

- 16.5 Routes of Administration for Delivery of Proteins and Peptides 658
- 16.6 Approaches for Enhancing Delivery of Proteins and Peptides via Oral Route 662
- 16.7 Novel Approaches 677
- 16.8 Conclusion 678
- Abbreviations 679
- References 680
- Further Reading 684
- 17. Nanocarriers in Different Preclinical and Clinical Stages**
- SARA NIDAL ABED, PRAN KISHORE DEB, HIBA SALIM SURCHI, SARAH FALAH KOKAZ, SAADH MOHAMED JAMAL, SHANTANU BANDOPADHYAY AND RAKESH K. TEKADE
- 17.1 Introduction 686
- 17.2 Background of the Nanotechnology 687
- 17.3 Preclinical Updates on Various Nanocarriers 694
- 17.4 Nanoparticle-Based Products Under Clinical Trials 698
- 17.5 Failed Clinical Trials Using Nanocarriers for Various Biomedical Applications: Reasons Behind 702
- 17.6 Current Regulatory Status of Various Nanocarriers 703
- 17.7 Commercially Available Nanoparticles Delivery Systems 709
- 17.8 Commentary on Hurdles in Clinical Translation of Various Nanotechnology Products 716
- 17.9 Conclusion 721
- Abbreviation 722
- References 724
- Further Reading 731
- 18. Clinical Aspects and Regulatory Requirements for Nanomedicines**
- VISHAKHA TAMBE, RAHUL MAHESHWARI, YASHU CHOURASIYA, HIRA CHOUDHURY, BAPI GORAIN AND RAKESH K. TEKADE
- 18.1 Introduction 734
- 18.2 Regulatory Perspective 736
- 18.3 Role of the Various Regulatory Agencies Involved in Regulation of Nanomedicines 739
- 18.4 Clinical Aspects of Nanomedicines 743
- 18.5 Ethics in Nanomedicines 747
- 18.6 Conclusion 748
- Acknowledgement 748
- Abbreviations 749
- References 749
- Index 753**